Power3 Secures Exclusive Rights From UT M. D. Anderson Cancer Center for Early Detection Test, Biomarkers and Targets for Drug Resistant Cancer
THE WOODLANDS, Texas, Aug. 9 /PRNewswire-FirstCall/ — Power3 Medical Products, Inc. a leading proteomics company, today announced that it has obtained the exclusive worldwide license to patents and technologies for early detection screening tests, identified protein biomarkers and drug targets for cancer patients’ resistance to drug therapy. The technology was developed through joint collaboration between the scientific team of Power3 Medical and The University of Texas M. D. Anderson Cancer Center.
According to Dr. Ira L. Goldknopf, Chief Scientific Officer and Head of the Scientific Team at Power3, “By utilizing our very sensitive and reproducible proteomic methods with definitive patient samples, we discovered a series of proteins whose concentrations in the bone marrow aspirate samples, taken from Chronic Myelogenous Leukemia (CML) patients before treatment, demonstrated a consistent correlation with whether the patients subsequently responded to the treatment with a particular drug. The identities of these proteins, which apparently detect the presence of drug resistant cancer cells prior to treatment, also indicate a potential to design drugs to kill both sensitive and resistant cancer cells.”
“By the time drug resistance is detected in CML by current technology it is usually too late to save the patient. This technology holds the promise of detecting cancer resistance to drugs before treatment begins and offers the possibility of designing drugs to increase their effectiveness to defeat resistant cancer and to thereby prevent recurrence of the disease,” comments Steven B. Rash, Chairman and CEO of Power3 Medical.
About Power3 Medical Products
Power3 Medical Products, http://www.power3medical.com/, is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company’s identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
About The University of Texas M. D. Anderson Cancer Center
M. D. Anderson, a nonprofit institution founded in 1941, has established an international reputation as one of the world’s preeminent centers for cancer patient care, research, education and prevention. A multidisciplinary approach and dedication to translational research, education and prevention are hallmarks of M. D. Anderson, which also holds the distinction of being designated by the National Cancer Institute (NCI) as one of the first three Comprehensive Cancer Centers in the United States. For 16 consecutive years, it has been ranked one of the top two cancer centers in the United States by U.S. News & World Report’s “America’s Best Hospitals.”
M. D. Anderson has provided care for more than 600,000 cancer patients since 1944 and 70,000 in the last year alone. Its faculty currently holds more NCI research grants and grant dollars than any other academic center in the United States. In 2003, nearly 1,000 new patients from outside the United States came to M. D. Anderson for care. http://www.mdanderson.org/.
This press release contains “forward-looking” statements, including statements related to the outcome of certain actions being taken by the Company and the anticipated timing and nature of filings with the Securities and Exchange Commission. Any statements in this press release, which are not statements of historical fact, may be deemed to be forward-looking statements. Words such as “will,”"expects,”"anticipates,”"plans,” and similar expressions are intended to identify these forward-looking statements. There are a number of important factors and uncertainties that could cause results to differ materially from those indicated by these forward-looking statements, including risks inherent in research and development activities; the ability to raise sufficient capital and obtain financing for the development activities; uncertainties associated with regulatory approvals; as well as other risks detailed from time to time in Power3′s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2003, and its reports on Form 10-QSB and Form 8-K. Power3 assumes no obligation to update forward-looking statements as a result of new information, future events or otherwise.
Contact: Corporate Steven Rash Chairman/CEO Power3 Medical Products, Inc. T: 281-466-1600
Power3 Medical Products, Inc.
CONTACT: Steven Rash, Chairman – CEO of Power3 Medical Products, Inc.,+1-281-466-1600
Web site: http://www.power3medical.com/http://www.mdanderson.org/